1
|
van Kraaij SJW, Pereira DR, Smal B, Summo L, Konkel A, Lossie J, Busjahn A, Grammatopoulos TN, Klaassen E, Fischer R, Schunck WH, Gal P, Moerland M. Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease. Clin Transl Sci 2023. [PMID: 37177864 DOI: 10.1111/cts.13530] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 04/11/2023] [Accepted: 04/11/2023] [Indexed: 05/15/2023] Open
Abstract
The development of pharmacological therapies for mitochondrial diseases is hampered by the lack of tissue-level and circulating biomarkers reflecting effects of compounds on endothelial and mitochondrial function. This phase 0 study aimed to identify biomarkers differentiating between patients with mitochondrial disease and healthy volunteers (HVs). In this cross-sectional case-control study, eight participants with mitochondrial disease and eight HVs matched on age, sex, and body mass index underwent study assessments consisting of blood collection for evaluation of plasma and serum biomarkers, mitochondrial function in peripheral blood mononuclear cells (PBMCs), and an array of imaging methods for assessment of (micro)circulation. Plasma biomarkers GDF-15, IL-6, NT-proBNP, and cTNI were significantly elevated in patients compared to HVs, as were several clinical chemistry and hematology markers. No differences between groups were found for mitochondrial membrane potential, mitochondrial reactive oxygen production, oxygen consumption rate, or extracellular acidification rate in PBMCs. Imaging revealed significantly higher nicotinamide-adenine-dinucleotide-hydrogen (NADH) content in skin as well as reduced passive leg movement-induced hyperemia in patients. This study confirmed results of earlier studies regarding plasma biomarkers in mitochondrial disease and identified several imaging techniques that could detect functional differences at the tissue level between participants with mitochondrial disease and HVs. However, assays of mitochondrial function in PBMCs did not show differences between participants with mitochondrial disease and HVs, possibly reflecting compensatory mechanisms and heterogeneity in mutational load. In future clinical trials, using a mix of imaging and blood-based biomarkers may be advisable, as well as combining these with an in vivo challenge to disturb homeostasis.
Collapse
Affiliation(s)
- Sebastiaan J W van Kraaij
- Centre for Human Drug Research, Leiden, The Netherlands
- Leiden University Medical Centre, Leiden, The Netherlands
| | | | - Bastiaan Smal
- Centre for Human Drug Research, Leiden, The Netherlands
| | | | | | | | | | | | | | | | - Wolf-Hagen Schunck
- OMEICOS Therapeutics GmbH, Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Pim Gal
- Centre for Human Drug Research, Leiden, The Netherlands
- Leiden University Medical Centre, Leiden, The Netherlands
| | - Matthijs Moerland
- Centre for Human Drug Research, Leiden, The Netherlands
- Leiden University Medical Centre, Leiden, The Netherlands
| |
Collapse
|
2
|
Cox F, Kwaks T, Brandenburg B, Koldijk MH, Klaren V, Smal B, Korse HJWM, Geelen E, Tettero L, Zuijdgeest D, Stoop EJM, Saeland E, Vogels R, Friesen RHE, Koudstaal W, Goudsmit J. HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids. Front Immunol 2016; 7:399. [PMID: 27746785 PMCID: PMC5040702 DOI: 10.3389/fimmu.2016.00399] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Accepted: 09/20/2016] [Indexed: 12/17/2022] Open
Abstract
Interactions with receptors for the Fc region of IgG (FcγRs) have been shown to contribute to the in vivo protection against influenza A viruses provided by broadly neutralizing antibodies (bnAbs) that bind to the viral hemagglutinin (HA) stem. In particular, Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) has been shown to contribute to protection by stem-binding bnAbs. Fc-mediated effector functions appear not to contribute to protection provided by strain-specific HA head-binding antibodies. We used a panel of anti-stem and anti-head influenza A and B monoclonal antibodies with identical human IgG1 Fc domains and investigated their ability to mediate ADCC-associated FcγRIIIa activation. Antibodies which do not interfere with sialic acid binding of HA can mediate FcγRIIIa activation. However, the FcγRIIIa activation was inhibited when a mutant HA, unable to bind sialic acids, was used. Antibodies which block sialic acid receptor interactions of HA interfered with FcγRIIIa activation. The inhibition of FcγRIIIa activation by HA head-binding and sialic acid receptor-blocking antibodies was confirmed in plasma samples of H5N1 vaccinated human subjects. Together, these results suggest that in addition to Fc–FcγR binding, interactions between HA and sialic acids on immune cells are required for optimal Fc-mediated effector functions by anti-HA antibodies.
Collapse
Affiliation(s)
- Freek Cox
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Ted Kwaks
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Boerries Brandenburg
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Martin H Koldijk
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Vincent Klaren
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Bastiaan Smal
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Hans J W M Korse
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Eric Geelen
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Lisanne Tettero
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - David Zuijdgeest
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Esther J M Stoop
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Eirikur Saeland
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Ronald Vogels
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Robert H E Friesen
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Wouter Koudstaal
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| | - Jaap Goudsmit
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson , Leiden , Netherlands
| |
Collapse
|